Patients with NF2-related VS undergoing bevacizumab therapy were used as a disease model to test this new analysis approach due to both the previously reported predictive potential of DCE-MRI in this tumour group and the purported vascular normalization mechanism of anti-VEGF therapy that has been demonstrated in pre-clinical studies, which could be interrogated through our DCE-MRI approach. The gene discussed is NF2; the disease is neoplasm.